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Nuclear receptors (NRs) rely on coregulators (coactivators and corepressors) to modulate the transcription
of target genes. By interacting with nucleosome remodeling complexes, NR coactivators potentiate
transcription, whereas corepressors inhibit transcription of the target genes. Metastasis-associated proteins
(MTA) represent an emerging family of novel NR coregulators. In general, MTA family members form
independent nucleosome remodeling and deacetylation (NuRD) complexes and repress the transcription of
different genes by recruiting histone deacetylases onto their target genes. However, MTA1 also acts as a
coactivator in a promoter-context dependent manner. Recent findings that repression of estrogen receptor
transactivation functions by MTA1, MTA1s, and MTA2 and regulation of MTA3 by estrogen signaling have
indicated the significance of these proteins in NR signaling. Here, we highlight the action of MTA proteins on
NR signaling and their roles in pathophysiological conditions.
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Introduction
Metastasis is a complex disease involving a series of
events that includes stimulation or repression of numerous
gene products in a coordinate manner, resulting in the
invasion of neoplastic cells and detachment from the
primary tumors, penetration into blood and lymphatics,
arrest by adhesion at distant sites, extravasation,
induction of angiogenesis, evasion of host antitumor
responses, and growth at metastatic sites [Nicolson,
1988].To identify the genes potentially involved in breast
cancer invasion and metastasis, Toh et al. performed
differential screening of a cDNA library of metastatic and
nonmetastatic adenocarcinoma cell lines from rat
mammary glands and cloned a novel gene known as the
metastasis-associated tumor gene (mta1) [Toh et al.,
1994]. Despite widespread overexpression of the MTA1
protein in human tumors, the molecular functions of the
MTA family remained a mystery until the proteomic
analysis of the nucleosome remodeling and deacetylation
(NuRD) complex identified MTA1 and MTA2 as integral
to the histone deacetylase (HDAC) complexes [Xue et
al., 1998; Zhang et al., 1998], thus providing clues about
the role of the MTA family of proteins in chromatin
remodeling. MTA3, the third member of the MTA family,
was identified as an estrogen-inducible gene product that
forms a distinct Mi-2/NuRD complex [Fujita et al., 2003].
MTA1s, a naturally occurring variant of MTA1, was
accidentally discovered by researchers pursuing the role
of MTA1 in transcriptional regulation of estrogen
receptor-α (ER) [Kumar et al., 2002]. MTA1s is generated
by alternative splicing at a cryptic splice-site in exon 14,
involving the deletion of 47 base pair nucleotides, and a
frame-shift involving the addition of 33 unique amino acids
with no homology among sequences from Genbank.The
resulting MTA1s gene product lacks the C-terminal region
of other MTA family members [Kumar et al., 2002]. Using
a polyclonal antibody against purified zymogen granule
membrane components from rat pancreas, researchers
identified ZG29p, a cDNA coding for the 29-kDa protein,
by immunoscreening a hormonally stimulated pancreas
cDNA library. ZG29p is an N-terminal truncated form of
MTA1, coded by the last seven exons of MTA1 and
present in the zymogen granules of the pancreas. ZG29p
mediates an interaction with amylase and is involved in
condensation-sorting in the exocrine rat pancreas [Kleene
et al., 2000].
Domain structure of the MTA family
MTA1 and MTA2 are polypeptides with molecular masses
of approximately 80 kDa and 70 kDa, respectively,
whereas MTA3 is smaller, approximately 65 kDa. Protein
alignment homology of the human MTA proteins revealed
68% and 73% homology of MTA2 and MTA3,
respectively, with MTA1.The highest homology was
concentrated in the N-terminal half of the proteins,
whereas the C-terminal regions of the MTA proteins were
divergent (Figure 1A and [Manavathi and Kumar, 2007]).
The MTA family, with the exception of the ZG29p variant,
contains one BAH domain, one ELM domain, and one
SANT domain, which is identical to the DNA binding
domain of myb-related proteins.The BAH, ELM, and
SANT domains among the MTA family members exhibit
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of these domains has not yet been directly tested; it is
currently hypothesized from studies of proteins containing
such domains. For example, the BAH domain is involved
in protein-protein interactions, whereas the SANT domain
interacts with histones [Grune et al., 2003; Oliver et al.,
2005]. Also, all MTA family proteins contain a GATA-like
zinc-finger and a DNA-binding domain found in the GATA
transcription factors. Unfortunately, experimental evidence
in support of a direct DNA-binding activity of MTA proteins
is lacking.The prototypic MTA1 contains two bipartite
nuclear localization signals and one basic amino acid-rich
nuclear localization signal [Manavathi and Kumar, 2007].
MTA2 contains one basic amino acid-rich nuclear
localization signal. MTA3 does not contain a predicted
nuclear localization signal, but localizes to both the
cytoplasmic and nuclear compartments. Although the
N-terminal sequences of MTA1, MTA2, and MTA3 are
similar, only MTA1 contains a proline-rich Src-homology
3 domain-interacting region at the C-terminus, providing
a biochemical basis for MTA1 interaction with the
signaling molecules [Manavathi and Kumar, 2007].
Figure 1.  Comparison of structural domains among MTA family
members and the components of the NuRD and Sin3 complexes.
A) Comparison of physical structures of the MTA family proteins. BAH,
ELM and SANT domains located at the N-terminus are highly conserved,
whereas the C-terminal region of MTA proteins is divergent. Identity (%),
percentage of amino acid homology among MTA family members. ZnF,
zinc finger; NLS-nuclear localization signal; AA, amino acids; PRO-rich,
proline rich domain. B) Schematic representation of components of the
NuRD complex, which is composed of seven polypeptides: Mi-2α/β,
MTA1/2, MBDs, p66, HDACs (HDAC1 and 2), RbAp46 and RbAp48.
Expression of the MTA genes
MTA genes represent a rapidly growing novel gene family
that includes three different genes encoded at three
separate loci (MTA1 at 14q; MTA2 at 11q; and MTA3 at
2q) with several alternative splice forms (MTA1s,
MTA1-ZG29p, and MTA3L) [Yaguchi et al., 2005].The
existing literature provided the handful of downstream
targets of MTA proteins; however, few studies have
addressed the regulators of these proteins. Recent
findings provide some clues about the regulation of MTA
protein expression. Heregulin, a ligand for HER3 and
HER4, has been shown to induce the expression of MTA1
in breast cancer cells [Mazumdar et al., 2001]. A recent
study that was aimed at isolating novel c-MYC targets by
expressing the conditional c-MYC/ER fusion protein in
the normal diploid human fibroblasts identified the MTA1
promoter as a C-MYC target [Zhang et al., 2005].The
MTA1 was found to be a mechanistic mediator of
c-MYC-regulated transformation. Further, MTA1 is also
transcriptionally upregulated under hypoxia through a
poorly understood mechanism [Yoo et al., 2006].
It has been demonstrated that estrogen regulates the
expression of MTA3 in breast cancer cells [Fujita et al.,
2004; Mishra et al., 2004a]. MTA3 contains half estrogen
response elements (ERE), along with AP-1 and SP-1
sites, and it has been shown that ER-α, AP-1, and SP-1
transcription factors directly bind onto these half ERE,
AP-1, and SP-1 elements on the MTA3 promoter,
respectively, and thereby strongly influence MTA3
transcription in breast cancer cells in a
hormone-dependent manner [Fujita et al., 2004; Mishra
et al., 2004a]. Expression of MTA3 appears to be
somewhat tissue-specific, as this protein expresses
predominantly in breast cancer cells and B-lymphocytes,
whereas MTA1 and MTA2 are ubiquitously expressed.
In contrast to MTA3, MTA2 promoter contains ETS-1
binding elements along with SP-1-binding motifs, and
MTA2 transcription is regulated by both ETS-1 and SP-1
[Xia and Zhang, 2001]. Information about the regulation
of ZP29 gene transcription is not available at this time.
Subcellular localization of the MTA
proteins
In general, the MTA proteins contain basic nuclear
localization signals and are predominantly localized in
the nucleus. Analysis of various mouse tissues suggested
that variable, but easily detectable, levels of MTA1 protein
are present in multiple organ systems, including lung,
liver, kidney, heart, and testes, thus suggesting a
physiologic function of MTA1 in normal cellular functions
[Mazumdar et al., 2001]. Similarly, MTA1
immunohistochemical assays have documented the
predominantly nuclear localization of MTA1 in various
cancerous tissues, including ovarian, lung, gastric, and
colorectal cancers [Manavathi and Kumar, 2007].
However, in human hepatocarcinoma (HCC) cells and in
human B-cell lymphomas, MTA1 localizes to both the
nucleus and cytoplasmic compartments [Moon et al.,
2004]. In contrast to MTA1, MTA3 localizes to both
cytoplasm and nucleus compartments, despite the lack
of a putative nuclear localization signal. MTA1s, a smaller
protein with 429 amino acids, is predominantly localized
in the cytoplasm owing to the loss of the nuclear
localization signal due to alternative splicing [Manavathi
and Kumar, 2007].
Posttranslational modifications of the
MTA proteins
Among MTA family members, MTA1 has been found to
be acetylated at lysine 626 by histone acetyltransferase
p300 in breast cancer cells [Gururaj et al., 2006].The
lysine 626 site of MTA1 is not conserved among the family
members.The acetylated MTA1 and RNA polymerase II
(Pol II) complex is recruited onto the BCAS3 promoter in
the vicinity of half-ERE elements [Gururaj et al., 2006]. It
appears that MTA1, a presumed corepressor of ER-α,
could also function as a coactivator and could stimulate
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an interesting possibility that the corepressor versus
coactivator activity of MTA1 may be influenced by
MTA1-binding partners, posttranslational modifications
of the protein, or both and that this could very well be
further affected in a promoter-context manner. MTA1 is
also a phosphoprotein (Da-Qiang Li and Kumar, personal
communication); however, the responsible kinase(s) are
unknown.
Catalytic activity of the MTA proteins
Currently, no evidence supports intrinsic enzymatic
activity of the MTA1 proteins. However, the presence of
MTA proteins (MTA1, MTA2, and MTA3) in NuRD
complexes supports the participation of MTA family
members in the deacetylation of histones [Toh et al.,
1994; Xue et al., 1998; Zhang et al., 1998] and putative
non-histone proteins [Manavathi and Kumar, 2007]. For
example, HDAC1-containing complex, known as PID,
contains MTA2 and HDAC2 and mediates the
deacetylation of p53 [Luo et al., 2000]. PID specifically
interacts with p53, and its level reduces the steady-state
levels of the acetylated p53. Consequently, deacetylated
p53 results in a reduced p53-dependent transcription, as
deacetylation of p53 induces its degradation through
MDM2, which eventually leads to p53-mediated cell
growth arrest and apoptosis [Luo et al., 2000]. Because
the levels of PID and MTA2 are especially high in the
rapidly dividing cells, there may be a functional interaction
between p53, PID, and MTA2, as well as p53
deacetylation, in the cancer cells.
Another notable target of the MTA and HDAC complexes
is the hypoxia-inducible factor 1 (HIF-1)α, the master
transcriptional regulator that facilitates adaptation to low
oxygen availability, commonly known as hypoxia [Yoo et
al., 2006].The expression of MTA1 has been shown to
be induced unexpectedly by hypoxia in breast cancer
cells, and its level correlates well with HIF-1α [Yoo et al.,
2006].
Furthermore, MTA1 enhances the stability and
transcriptional activity of HIF-1α under hypoxic stress.
The underlying mechanism involves the enhancement of
HIF-1α association with HDACs, resulting in the
deacetylation of HIF-1α, as deacetylated HIF-1α is
resistant to ARD1-mediated ubiquitin-proteosome
degradation [Yoo et al., 2006]. Since MTA1 is a
metastasis promoting gene under pathologic conditions
[Nicolson, 1988], the mechanistic role of MTA1 in HIF-1α
regulation may contribute to the metastatic role of MTA1
in cancer cells.
Because ER-α physically interacts with the MTA1-HDAC
complex [Mazumdar et al., 2001], and because ER-α is
an acetylated protein [Gururaj et al., 2006], the acetylation
status of which directly influences its transactivation
functions, it is possible that MTA1 may also regulate ER-α
functions by deacetylating ER-α.This possibility has been
experimentally tested, and indeed, ER-α is deacetylated
by the MTA2/HDAC complex, and the acetylation mutant
of ER-α exhibits less transcriptional activity (Figure 1B
and [Cui et al., 2006]).
Transcriptional repression of ER-α by
the MTA proteins
Estrogen, the ligand for ER, exerts its action by binding
to its cognate receptors (ER-α, ER-β and GPR30)
[Manavathi and Kumar, 2006]. ER-α and ER-β are
transcription and signaling factors. ER regulates cellular
functions by binding to the ERE elements on its target
genes.The transcriptional activity of ER is influenced by
a variety of coactivators and corepressors [McKenna and
O'Malley, 2002]. For example, coactivators such as p300
interact with ER-α and support the chromatin remodeling
by acetylating the histones around the target promoter
[McKenna and O'Malley, 2002]. In contrast, corepressor
complexes promote the condensation of chromatin,
leading to repression of the ability of the nuclear receptor
(NR) to promote transcription [McKenna and O'Malley,
2002]. NuRD is one such corepressor complex [Toh et
al., 1994; Xue et al., 1998; Zhang et al., 1998].The NuRD
complex contains seven polypeptides: HDAC1, HDAC2,
RbAp46, RbAp48, Mi-2α/β, MTA1/2, and p66. Another
complex, Six3, has a composition similar to NuRD and
also participates in the NR repression of target genes
[Ahringer, 2000]. In the NuRD complex, HDAC1 and
HDAC2 contribute to deacetylation; Mi-2α and Mi-2β
proteins with a chromodomain exhibit a DNA
helicase/ATPase activity; and RbAp46 and RbAp48
participate in histone binding [Brackertz et al., 2002].The
p66a and p66b proteins are involved in the interaction
with methyl-CpG binding domain proteins (MBD) 2 and
3 and also interact with the tails of all octamer histones
to enhance the MBD2-mediated repression [Brackertz et
al., 2002]. Further complexity in the role of p66 in the
NuRD complex arises from its sumoylation. Small
ubiquitin-like modifier (SUMO)-modified forms of p66α
efficiently interact with HDAC1, whereas RbAp46 binds
to SUMO-p66β [Gong et al., 2006]. Although all MTA
family proteins are found in NuRD complexes, these
proteins form distinct complexes and are thought to target
different sets of promoters [Bowen et al., 2004;Yao and
Yang, 2003].
Because the Mi-2/NuRD complex contains both histone
deacetylase and chromatin-remodeling ATPase activities,
it is thought that such complexes are involved in the
hypoacetylation of core histones and that
HDAC-containing complexes participate in transcriptional
repression. Although the presence of MTA proteins in
NuRD complexes has provided clues about the role of
MTA family members in chromatin regulation [Toh et al.,
1994; Xue et al., 1998; Zhang et al., 1998], direct targets
of MTAs were unknown until the discovery that MTA1
directly interacts with ER-α, HDAC1, and HDAC2
[Mazumdar et al., 2001].The NuRD complex interacts
with ER-α and represses its transcriptional activity in an
HDAC-sensitive manner [Mazumdar et al., 2001].
Subsequently, MTA1 was found to interact with other
proteins such as ménage á trois 1 (MAT1),
MTA1-interacting coactivator (MICoA), nuclear
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4 (LMO4) [Mishra et al., 2003; Singh et al., 2005;Talukder
et al., 2004;Talukder et al., 2003].
Using a yeast two-hybrid screen with the MTA1 C-terminal
domain as bait, Talukder et al identified MAT1 as an
MTA1-binding protein. MAT1 is an assembly and targeting
factor for cyclin-dependent kinase-activating kinase
(CAK), which has been shown to functionally interact with
general transcription factor TFIIH, a known inducer of ER
transactivation [Talukder et al., 2003]. Estrogen signaling
promotes nuclear translocation of MAT1 and interacts
with MTA1 in the nucleus. MAT1 binds to the C-terminal
GATA domain containing 389-441 amino acids and the
N-terminal bromo-domain containing 1-164 amino acids
of MTA1, whereas MTA1 binds to the N-terminal ring
finger domain of MAT1. MAT1 interacts with the (AF) 2
domain of ER-α and co-localizes with ER-α in the nucleus.
The interactions between CAK and MTA1 regulate the
transactivation activity of ER-α in a CAK-dependent
manner in breast cancer cells [Talukder et al., 2003].
MICoA is another well-characterized MTA1 binding
partner. MICoA is also an ER coactivator. MICoA
cooperates with other ER coactivators, such as p300,
and stimulates ER-transactivation functions by associating
with endogenous ER-α on its target promoters. MTA1
opposes MICoA-mediated ER-α transactivation functions
by recruiting HDACs [Mishra et al., 2003]. NRIF3, another
MTA1-binding protein, was also identified using a yeast
two-hybrid screen [Talukder et al., 2004]. Interestingly,
NRIF3 is an estrogen-inducible gene, and the NRIF3
protein functions as a coactivator for ER-α. NRIF3
interacts with MTA1 through its N-terminal domain,
whereas it interacts with ER-α through the NR box.
Because NRIF3’s box participates in its interaction with
ER-α, estrogen treatment displaces the MTA1/HDAC
complex from ER-α and modulates the sensitivity of
breast cancer cells to estrogen [Talukder et al., 2004]. In
addition, a recent study revealed that MTA1 interacts with
LMO4, a member of the LIM-only family of transcriptional
coregulatory proteins. MTA1 also intensifies the LMO4
protein’s repressor activity on ER-α, implying that LMO4
is a component of the MTA1 corepressor complex [Singh
et al., 2005]. It appears that MTA1 represses the ER
transactivation functions by recruiting the HDAC complex
and other corepressors on ER target genes, which leads
to ligand-independent metastasis phenotype (Figure 2,
Table 1).
The MTA1s protein, a naturally occurring splice variant
of MTA1, was discovered by researchers studying the
corepressive activity of MTA1 [Kumar et al., 2002]. MTA1s
localizes in the cytoplasm, and its C-terminal stretch of
33-amino acid residues bears no resemblance to any of
the previously reported protein sequences. Situated in
the early portion of this 33-amino acid region is an NR
box motif (LRILL). MTA1s uses this motif to interact and
bind with the AF2 domain of ER-α, leading to its
cytoplasmic sequestration and subsequent suppression
of genomic functions of ER-α (Figure 2). Cytoplasmic
sequestration of ER-α augments the rapid cytoplasmic
activities of ER, such as MAPK activation. Overexpression
of MTA1s in ER-positive breast cancer cells leads to an
aggressive phenotype.The nuclear magnetic resonance
(NMR)-aided structure of the novel 33-amino acid region
of MTA1s revealed its α-helix nature [Singh et al., 2006].
In silico modeling suggested that the NR box motif of the
33-amino acid region of MTA1s binds to the AF2 domain
(helix 12) of ER-α and, thus, might impair its interaction
with coactivators. Indeed, in tissue culture-based models,
the MTA1s 33 amino acid peptide inhibits the recruitment
of coactivators onto ER and inhibits its transactivation
functions. Further, the MTA1s peptide also exerts an
inhibitory effect on estrogen-induced proliferation of breast
cancer cells [Singh et al., 2006]. MTA1s has also been
shown to interact with casein kinase I-gamma2 (CK1γ2)
[Mishra et al., 2004b].
Figure 2.  Cartoon showing the roles played by MTA family
members in the nuclear receptor signaling pathway. MTA1 and
MTA1s are induced by various growth factors, Hypoxia and E2. MTA1
interacts with NuRD, while MTA2 associates with HDACs and represses
E2-ERα transactivation at EREs. MTA1 also interacts with p300 and
activates BCAS3 transcription. MTA1/2-HDACs complex also plays a role
in stabilization of p53 and HIF1-α through acetylation. MTA3 is activated
by ERα, associates with NuRD complex and represses Snail, an inhibitor
of E-cad, and thereby promotes EMT.
More recently, MTA2 has also been shown to bind to
ER-α in breast cancer cells. Like MTA1, MTA2 also
represses the transcriptional activity of ER-α by recruiting
HDACs onto the ER-α target chromatin (Figure 2 and
[Cui et al., 2006]). Moreover, the MTA2/HDAC complex
regulates the deacetylation of ER-α and, consequently,
its functions. All other MTA family interacting proteins are
summarized in Table 1.
Estrogen-MTA3–mediated regulation of
epithelial to mesenchymal transition
As discussed earlier, MTA3 has also been shown to form
a distinct Mi-2/NuRD complex [Fujita et al., 2003].The
MTA3-containing Mi-2/NuRD complex influences
E-cadherin expression in breast cancer cells by inhibiting
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transcription repressor Snail [Fujita et al., 2003], which
in turn controls the epithelial-to-mesenchymal transition
(EMT).This function of MTA3 is linked with the NR-ER-α
pathway, as MTA3 is a transcriptional target of ER-α. In
the presence of ligand, ER-α directly binds to the MTA3
promoter at the half-ERE/Sp1 binding site and stimulates
MTA3 transcription [Fujita et al., 2004; Mishra et al.,
2004a]. Because both MTA1 and MTA1s negatively
regulate ER-α function and because MTA3 is an
estrogen-regulated gene, any potential upregulation of
MTA1 or MTA1s may lead to repression of MTA3. As
regulated reduction in the level of MTA3 will lead to
upregulation of Snail, promotion of EMT, and metastasis
of breast cancer cells, these findings suggest a role for
MTA1 and MTA1s in the EMT process (Figure 2).
Table 1.  List of currently characterized MTA-interacting proteins.
MTA family of proteins interacts with various transcriptional complexes
including MICoA and NRIF3. Nuclear receptor ERα also interacts with
MTA1, MTA1s and MTA2. Other interacting proteins include p53, BCL6,
CAK, CK1γ2 and MBD3.
MTA1 and hormone action during
mammary gland development
Because ER-α plays a pivotal role in mammary gland
development and MTA1 is a potent transcriptional
corepressor of ER-α, MTA1 is also thought to play an
important role in mammary gland development.
Consistent with this notion, overexpression of the
mammary tumor-like virus (MMTV)-MTA1 transgene in
the mouse mammary gland resulted in increased ductal
extension, enhanced ductal branching, and proliferation
[Bagheri-Yarmand et al., 2004]. In addition, the mammary
glands of MMTV-MTA1 mice exhibit an accelerated
lobuloalveolar-like precocious differentiation, decreased
pregnancy-associated morphogenesis, and delayed
involution and tumorigenesis. Furthermore, the noted
increase in ductal growth and extensive ductal branching
in MTA1-transgenic mice was attributed, at least in part,
to the alteration in the ratios of progesterone receptor
isoforms [Bagheri-Yarmand et al., 2004]. In contrast to
the hyperbranching and tumor formation in
MTA1-transgenic mice, MTA3-transgenic mice exhibit
hypobranching [Zhang et al., 2006a].These contrasting
physiological differences displayed by MTA family
members also support the notion of a lack of functional
redundancy among individual MTA proteins.
Preservation of corepressor activity of
MTA1 in Caenorhabditis elegans
Because the NuRD complex plays an important role in
nucleosome remodeling and transcriptional regulation, it
is anticipated that components of the NuRD complex will
play a role in embryonic development. Initially, the
biological functions of Mi-2 proteins and components of
the NuRD complex forecasted a potential role of the
NuRD complex in Caenorhabditis elegans [von Zelewsky
et al., 2000]. Indeed, studies with the MTA1 homologues
egl-27 and egr-1 in C. elegans identified inactivation of
both of these genes in embryos, leading to abnormal
patterning of the cells in the embryo.These findings
suggested that EGL-27-containing protein complexes
regulate the activity of transcription factors involved in
embryonic patterning [von Zelewsky et al., 2000].
Furthermore, egr-1 and egl-27 proteins, along with the
components of NuRD complex, antagonize the
development of vulval tissue, which is induced by the Ras
signal transduction pathway. In this pathway, the
MTA1-related genes egr-1 and egl-27 act in the synMuvA
pathway to repress vulval developmental target genes
by local histone deacetylation, which is important for
vulval development and embryonic patterning [Chen and
Han, 2001].These studies on developmental aspects
identify the importance of MTA coregulators and
preservation of their function as transcriptional repressors
in chromatin regulation.
MTA proteins in diseases
Metastasis is the major cause of morbidity and mortality
among patients with cancer. Data from cell-based model
systems and mouse models have firmly established the
significance of MTA1 in cancer metastasis [Manavathi
and Kumar, 2007]. For example, MTA1 overexpression
in mouse mammary gland epithelium leads to the
formation of mammary gland adenocarcinomas
[Bagheri-Yarmand et al., 2004]. In addition,
MMTV-PyV-mT-transgenic mice, which represent a
reliable model for multistage tumorigenesis of human
breast cancer, exhibited an altered MTA1 expression in
both premalignant lesions and malignant breast
carcinoma [Zhang et al., 2006b].These tumors exhibited
an elevated MTA1 nuclear expression and MTA1 in the
center of late-stage tumors. In addition to breast cancer,
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70 endometrial adenocarcinomas of various grades
showed increased expression of MTA1 in 53 (75.7%)
tumors [Balasenthil et al., 2006]. Moreover, MTA1
overexpression was also found in a tissue microarray
analysis of 102 gastrointestinal carcinoids [Kidd et al.,
2006]. In another study of gastrointestinal carcinoma
tumors, 13 (38.2%) of 34 patients with gastric carcinoma
showed overexpression of MTA1 mRNA.These findings
suggest that higher rates of serosal invasion and lymph
node metastasis are linked with MTA1 overexpression
and tend to have a higher rate of vascular involvement
in these carcinomas [Toh et al., 1997].
Increased expression of MTA1 mRNA was also observed
from normal to tumor tissue in human colorectal
carcinoma and HCC cells [Giannini and Cavallini, 2005;
Hamatsu et al., 2003]. Furthermore, another study
showed that MTA1 overexpression correlates well with
the acetylated histone 4 in esophageal squamous cell
carcinomas [Toh et al., 2004].This study revealed that
30 (42.9%) of 70 samples (from normal tissue to cancer)
displayed overexpression of the MTA1 protein; such
tumors invaded deeper into the esophageal wall and
these patients showed a significantly higher degree of
lymph node metastasis, higher pathological stage, more
lymphatic involvement, and poorer prognosis than the
remaining cases. A DNA microarray analysis combined
with immunohistochemistry analysis showed that MTA1
is also selectively overexpressed in metastatic prostate
cancer compared with clinically localized prostate cancer
and benign prostate tissue [Hofer et al., 2004]. An
analysis of 74 non-small cell lung cancer (NSCLC)
samples revealed higher MTA1 mRNA levels in NSCLC
samples without lymph node metastasis [Sasaki et al.,
2002]. In thymomas, the MTA1 mRNA level was
significantly higher in stage IV thymoma than in stage I
and II thymomas [Sasaki et al., 2001].
MTA1 also appears to be involved in the development of
lymphomas. Data mining analysis of public expression
array datasets using Oncomine 2 showed that 75 out of
76 specimens of human lymphomas (98.6%) exhibited
MTA1 expression [Balasenthil et al., 2007]. MTA1
expression was observed in the nuclei (32%), as well as
in both nucleus and cytoplasm (68%) of diffuse large
B-cell lymphoma cases.These data are further supported
by the finding that MTA1 transgenic mice, which
developed breast adenocarcinoma [Singh et al., 2006],
also developed lymphomas during later stages of their
life span [Balasenthil et al., 2007]. Further overexpression
of MTA1 was observed in various human lymphoma and
leukemia cell lines [Balasenthil et al., 2007].These
findings implicate MTA1 in the development of
spontaneous B-cell lymphomas.Very little information is
available regarding the roles of MTA2 and MTA3 in
human cancers.
Future challenges
This review highlighted the biological significance of the
MTA proteins in the context of nuclear receptor biology.
Because the expression of MTA family members is not
restricted to cancer cells, one of the major outstanding
issues in MTA family research remains the lack of
understanding as to the physiological functions and
underlying mechanisms in normal cells. On the basis of
available data and the fact that MTA1 represents a master
coregulatory molecule, it is very likely that MTA1
deregulation may be involved in human diseases other
than cancer. Because MTA family members were found
in distinct subcellular compartments, it is important to
understand the underlying biochemical basis of differential
subcellular localization and whether it is further affected
by extracellular signals. Furthermore, to fully appreciate
the master regulatory function of MTA1 (or other MTA
family members), it is of paramount importance to
understand the nature of the biochemical switch
responsible for corepressor versus coactivator activity of
MTA1. In addition to further researching the cellular
functions of MTA1, there is a clear need to intensify
research connecting the various domains of MTA1 (or
other family members) with specific cellular function.
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